Lantern Pharma Inc. (LTRN)
NASDAQ: LTRN · Real-Time Price · USD
2.240
-0.220 (-8.94%)
At close: Apr 28, 2026, 4:00 PM EDT
2.340
+0.100 (4.46%)
After-hours: Apr 28, 2026, 7:41 PM EDT
Lantern Pharma Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Lantern Pharma.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Lantern Pharma.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Lake Street | Lake Street | Strong Buy Initiates $25 | Strong Buy | Initiates | $25 | +1,016.07% | Apr 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Apr 25, 2024 |
| EF Hutton | EF Hutton | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +391.07% | Aug 10, 2023 |
| EF Hutton | EF Hutton | Strong Buy Maintains $11 | Strong Buy | Maintains | $11 | +391.07% | Jun 26, 2023 |
| EF Hutton | EF Hutton | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +391.07% | May 25, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.95
from -1.57
EPS Next Year
-2.06
from -1.95
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | n/a | |
| Avg | n/a | n/a | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.01 | -2.12 | |||
| Avg | -1.95 | -2.06 | |||
| Low | -1.87 | -1.98 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.